Drugs / ALG-010133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04485663 | Aug 2020 → Mar 2022 | chronic hepatitis B virus infection | Aligos Therapeutics | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-01-06 | Aligos Therapeutics | Results Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133 aligos.com ↗
This decision is based on emerging data from the Phase 1 Study ALG-010133-101 that indicate that at the projected efficacious dose (400 mg, estimated to achieve liver exposures >3 x EC90 for HBsAg inhibition) there is no meaningful HBsAg reduction. |
| 2021-11-12 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021 aligos.com ↗
Triple combinations of the siRNA ALG-125755 and STOPS ALG-010133 with the ASO ALG-020572 showed additive activity in reducing HBsAg and demonstrated a dose-dependent response with respect to the ASO. |
| 2021-02-03 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver aligos.com ↗
Two other poster presentations entitled “Excellent preclinical characteristics of ALG-000184, a prodrug of the HBV capsid assembly modulator ALG-001075” and “ALG-020572, a next generation hepatitis B virus (HBV) antisense oligonucleotide (ASO) with bridged nucleic acid chemistry, has a significantly improved preclinical profile” highlight the nonclinical characteristics of ALG-000184 and its parent compound, ALG-001075, and ALG-020572, Aligos’ ASO candidate for chronic hepatitis B that significantly improves upon other ASOs in terms of nonclinical safety and efficacy. |
| 2020-06-18 | Aligos Therapeutics | Regulatory Aligos Therapeutics Submits Clinical Trial Application for Chronic Hepatitis B Oligonucleotide Candidate ALG-010133 aligos.com ↗
Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted antiviral therapies directed against chronic hepatitis B (CHB) and COVID-19 and therapeutics for NASH, today announced that it has submitted its first clinical trial application for a first-in-human Phase 1a/b study evaluating ALG-010133. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-010133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04485663 ↗ |
| Route | Subcutaneous | “Subcutaneous injections of ALG-010133” NCT04485663 ↗ |